CMC Biologics Announces Agreement with Daiichi Sankyo to Develop and Manufacture Antibodies

31-Oct-2011 - Denmark

CMC Biologics announces the execution of an agreement with Daiichi Sankyo Co., Ltd. to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. The two companies have recently begun work on thier first joint project at CMC Biologics´Bothell manufacturing facility. Specific terms of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous